Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:MGTX NASDAQ:NAMS NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.27-0.1%$28.44$19.05▼$32.56$3.83B0.742.53 million shs1.46 million shsMGTXMeiraGTx$9.00-6.0%$9.50$5.47▼$11.85$886.27M1.26781,470 shs693,694 shsNAMSNewAmsterdam Pharma$31.52-3.5%$33.52$17.63▼$42.21$3.82B0.071.67 million shs1.11 million shsVKTXViking Therapeutics$28.45-4.5%$32.28$22.96▼$43.15$3.46B0.691.75 million shs2.73 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.03%0.00%+1.39%+29.08%+23.72%MGTXMeiraGTx+1.92%-4.30%-1.85%+36.71%+75.27%NAMSNewAmsterdam Pharma+1.74%-7.76%+9.33%+9.41%+68.49%VKTXViking Therapeutics+1.53%-7.49%-4.89%-9.70%+10.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.27-0.1%$28.44$19.05▼$32.56$3.83B0.742.53 million shs1.46 million shsMGTXMeiraGTx$9.00-6.0%$9.50$5.47▼$11.85$886.27M1.26781,470 shs693,694 shsNAMSNewAmsterdam Pharma$31.52-3.5%$33.52$17.63▼$42.21$3.82B0.071.67 million shs1.11 million shsVKTXViking Therapeutics$28.45-4.5%$32.28$22.96▼$43.15$3.46B0.691.75 million shs2.73 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+0.03%0.00%+1.39%+29.08%+23.72%MGTXMeiraGTx+1.92%-4.30%-1.85%+36.71%+75.27%NAMSNewAmsterdam Pharma+1.74%-7.76%+9.33%+9.41%+68.49%VKTXViking Therapeutics+1.53%-7.49%-4.89%-9.70%+10.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.002.33% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.83187.04% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6054.19% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60229.00% UpsideCurrent Analyst Ratings BreakdownLatest MGTX, NAMS, CPRX, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/28/2026VKTXViking Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$89.005/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.005/26/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.005/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/7/2026CPRXCatalyst Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.50$2.92 per share10.70$7.76 per share4.03MGTXMeiraGTx$81.39M10.24N/AN/A($0.07) per share-128.57NAMSNewAmsterdam Pharma$22.50M163.76N/AN/A$5.97 per share5.28VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7417.9710.150.9537.08%35.76%31.31%8/5/2026 (Estimated)MGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%-1,065.47%-54.96%8/13/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest MGTX, NAMS, CPRX, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84MGTXMeiraGTxN/A0.550.55NAMSNewAmsterdam PharmaN/A9.769.76VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%MGTXMeiraGTx67.48%NAMSNewAmsterdam Pharma89.89%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%MGTXMeiraGTx7.50%NAMSNewAmsterdam Pharma12.74%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.38 million109.65 millionOptionableMGTXMeiraGTx30092.61 million85.66 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableMGTX, NAMS, CPRX, and VKTX HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderJune 4 at 9:54 PM | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderJune 4 at 6:45 PM | zacks.comViking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 4 at 4:03 PM | seekingalpha.comShould Viking’s VK2735 Obesity Program Advancements Require Action From Viking Therapeutics (VKTX) Investors?June 3 at 5:38 PM | finance.yahoo.comVKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% UpsideJune 2 at 8:24 PM | stocktwits.comSLake Street initiates coverage of Viking Therapeutics (VKTX) with buy recommendationMay 29, 2026 | msn.comWhy Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?May 29, 2026 | finance.yahoo.comWhy Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?May 29, 2026 | zacks.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderMay 28, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to ConsiderMay 28, 2026 | zacks.comViking Therapeutics (VKTX) Initiated with a Buy at Truist FinancialMay 28, 2026 | theglobeandmail.comIf Viking Therapeutics Is Acquired, Here's Who WinsMay 26, 2026 | 247wallst.comDon't Buy Viking Therapeutics Stock Until You Read ThisMay 25, 2026 | fool.comA Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent ReturnsMay 25, 2026 | finance.yahoo.comIs Viking Therapeutics a Top Takeover Target?May 23, 2026 | fool.com2 Stocks That Could Realistically Double by 2030May 22, 2026 | fool.comCan Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?May 21, 2026 | zacks.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | finance.yahoo.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21, 2026 | prnewswire.comBest Weight Loss Drug Stocks to Buy in 2026May 20, 2026 | fool.com75,475 Shares in Viking Therapeutics, Inc. $VKTX Bought by Channel Wealth LLCMay 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, NAMS, CPRX, and VKTX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.27 -0.02 (-0.06%) Closing price 04:00 PM EasternExtended Trading$31.28 +0.01 (+0.03%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.MeiraGTx NASDAQ:MGTX$9.00 -0.57 (-5.96%) Closing price 04:00 PM EasternExtended Trading$8.99 -0.01 (-0.06%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$31.52 -1.15 (-3.52%) Closing price 04:00 PM EasternExtended Trading$32.46 +0.94 (+2.98%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Viking Therapeutics NASDAQ:VKTX$28.45 -1.33 (-4.47%) Closing price 04:00 PM EasternExtended Trading$28.62 +0.17 (+0.59%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
